Method for treating patients suffering from chronic brucellosis

FIELD: medicine.

SUBSTANCE: for treating patients suffering from chronic brucellosis, therapeutic complex includes an antibiotic, as well as Licopid and Tamerite. The preparations are introduced in therapeutic doses.

EFFECT: choice of specific preparations from the group of immunomodulators and antioxidants for specific infections provides long remission and prevention of unfavourable outcome of brucellosis.

3 ex, 3 tbl, 1 dwg

 

The invention relates to medicine, for treatment of infectious diseases, in particular for the treatment of patients with chronic brucellosis. The method of treatment includes the introduction of the antioxidant drug tamerica and immunomodulator licopid in combination with antibacterial, anti-inflammatory and desensibilisation drugs, which allows to normalize the functional state of the antioxidant and immune systems and promotes long-term remission in patients with chronic brucellosis.

Know the use for the treatment of patients with chronic brucellosis in the acute stage of antibiotics, antibiotics in combination with immunomodulators. So, Apothecium (2003) to enhance specific immunity and desensitization is recommended the use of therapeutic brucellosis vaccine (TWT) intravenously, intramuscularly, subcutaneously and/or intradermally. Preference is given subcutaneous and intradermal introduction of the vaccine [A.P. Kazantsev Brucellosis // Manual of infectious diseases / edited by Corr.-Corr. Russian Academy of medical Sciences, Professor Uwielbia - SPb.: "Publishing a Book", 2003 - 108-117]. This method has the following disadvantages: therapy is carried out without taking into account the antioxidant status and immune systems, which are important in the pathogenesis, course and outcome of chronic brucellosis infection.

Viglucci et al. (2007) consider Naib is more effective injection TWT, providing a regulating effect on the specific reactivity of patients with chronic brucellosis [Selected lectures on infectious diseases and epidemiology / Under the General editorship of Prof. Viglucci, Professor Samarova. - Rostov-on-don: Phoenix, M: RSMU, 2007. - S-155].

However, this therapy has contributed only a temporary remission or was unsuccessful. However, the study of a number of authors have shown that TWT causes in patients with brucellosis increased sensitization and amplification of autoimmune manifestations, that is, it is a risk factor activation of Brucella infection [N. Ostrovsky. Brucellosis // Lectures on infectious diseases. Ed. by Acad. Russian Academy of medical Sciences Prof. N.d.yshuk and professional Washingtonova. - M.: Medicine, 2007].

Thus, widely used in the past specific antigenaemia (TWT), as established in recent years, causing an increase in the specific sensitization of the organism contributes to autoimmune manifestations, the transition process in the system irreversible defeat (collagenosis). None of the currently existing methods of treatment of patients with chronic brucellosis, including with the use of TWT, which is the closest analogue (prototype) of the invention, does not provide a lasting effect, but causes a number of adverse reactions that indicates a lack of studying the activity of pathogenesis and the need to improve pathogenetic therapy of chronic brucellosis infection.

Instead TWT recommended for brucellosis using drugs (decaris, immunofan, thymalin and others), corrective immunological status and not having a sensitizing effect [N. Ostrovsky. Brucellosis / Lectures on infectious diseases. Ed. N.d.yshuk, Washingtonova. - M.: Medicine, 2007. - S].

The study of individual aspects of the pathogenesis of chronic brucellosis is devoted to a large number of studies, however, the essence of his hitherto not been disclosed. In recent years, domestic and foreign researchers paid much attention to the role of nonspecific resistance of the organism (NRA) in the pathogenesis of infectious and non-communicable diseases [Akhmedov D.R. Clinical and pathogenetic value of the antioxidant system in infectious diseases // Clinical medicine. - 1994. No. 1. - P.24-26; Sokolov V.V. Thioldisulfide the ratio of blood as an indicator of the state of nonspecific resistance of the organism. - St. Petersburg, 1996. - 30 S.; Denialbeavis SM Clinical-pathogenetic evaluation of antioxidant status and immune systems in patients with brucellosis. - Diss. CMN - Makhachkala, 2000. - 156; YU.V. Medvedev, Tolstoy ROAD Hypoxia and free radicals in the development of pathological conditions. - M., 2000. - P.129-131; Slater T. Concluding remarks // Am. G. Clin. Nutr., 1991. - (Sappl) 3945-3965].

Found that extremely important frame link guides the m molecular mechanisms of the NRA is the antioxidant system (AOS) [Sokolov V.V. Thioldisulfide the ratio of blood as an indicator of the state of nonspecific resistance of the organism. - St. Petersburg, 1996. - 30].

It is known that some diseases develops antioxidant deficiency, which contributes to damage of immune cells and immune dysfunction. In patients with chronic brucellosis comprehensive study of antioxidant status and immune systems had not been previously conducted. In this regard, to assess individual mechanisms of the pathogenesis of brucellosis infection we studied the functional state of the antioxidant and immune systems, when this was first revealed in violation of the functional activity of the immune system and thioldisulfide link AOC in patients with chronic brucellosis.

As the prototype is set to the traditional method of treating patients with chronic brucellosis. This method consists in the following: conducting causal (antibacterial), pathogenetic treatment of brucellosis vaccine (immunomodulatory, desensitizing action), bracing and physical therapy [A.P. Kazantsev Brucellosis // Manual of infectious diseases / edited by Corr.-Corr. Russian Academy of medical Sciences, Professor Uwielbia - SPb.: "Publishing a Book", 2003. - 108-117].

The purpose of the invention is to improve the efficiency of treatment of patients with chronic brucellosis under sub - and decompensation based on what vosstanovleniya redox and immune homeostasis.

The inventive method consists in the following: patients with chronic brucellosis after studying the functional state of the antioxidant and immune systems is assigned to combined therapy with the inclusion of the antioxidant drug tamerica and immunomodulator licopid.

The aim is achieved in that during the treatment of patients with chronic brucellosis antibiotics were prescribed anti-oxidant (Americom) and immunomodulatory (Likopid) therapy.

Domestic drug "Tumeric" (registration number 2000/113/5 from 03.04.2000,) is a synthetic derivative of aminophthalhydrazide. The drug is available in vials of 10 ml with liofilizovane powder 100 mg white soluble in water.

Tumeric has antioxidant, immunomodulatory and anti-inflammatory action. Antioxidant effect of tamerica is implemented by reducing oxygen consumption hyperactivemenu by macrophages with subsequent reduction in the generation of oxygen radicals. Immunomodulatory effect is manifested in the normalization of antigen presenting and secretory function of cells of the monocyte-macrophage series, stimulation of microbiocides neutrophils and cytotoxicity of natural killer cells. Anti-inflammatory effect of the drug is due to its JV is the ability of reversible for 10-12 hours to inhibit the excess production by macrophages factor-alpha tumor necrosis, interleukin-1, nitrocompounds, reactive oxygen species and the severity of intoxication.

Domestic drug "Likopid (N acetylglucosaminyl-1-4-N-acetylmuramyl-L-alanyl-D-isoglutamine) is a synthetic analog of the structural fragment of the cell wall of bacteria (Registration certificate №95/211/4). The drug is synthesized in 1995 at the Institute of Bioorganic chemistry named. Shemyakin and Ovchinnikov Russian Academy of Sciences. Likopid stimulates the functional activity of macrophages and cytokines synthesis and does not contain bacterial contaminants, which could cause side effects. With these properties is its good tolerance by patients. The drug is available in tablets of 1 and 10 mg. Assign an adult inside before meals for 10 mg or sublingual 1 mg for 10 days [Mashkovsky PPM Medicines.- M: LLC "Publishing house New Wave", 2005. - S].

To confirm the effectiveness of the selected method study was conducted in 2 groups of patients with chronic brucellosis.

Method of treatment of patients with chronic brucellosis using tamerica and licopid on the background of traditional therapies used for the first time. The method has been used in the treatment of 162 patients with chronic brucellosis in the stage of de - and subcompensation. Patients received Tamarit intramuscularly at a dose of 100 mg 2 times a day for 10 days, followed by 100 mg 1 time in denv for 20 days, Likopid inside before meals for 10 mg 2 times a day for 20 days.

Clinical and laboratory data obtained in dynamics indicate pronounced clinical effect and correction of violations of the anti-oxidant and immune systems when using the proposed method for the treatment of patients with chronic brucellosis in the acute phase.

Examples of specific implementation method:

Example 1. Patient R., 43, case history No. 1398, he entered RCIB Makhachkala 30.03.05, with complaints of high fever, headache, General weakness, fatigue, sweating, chills, weight loss, pain in knee joints, myalgia. From the anamnesis of illness: sore since 2003, the Disease began with fever, sweating, pain in the joints. Were on treatment at the Republican clinical hospital (Makhachkala). Of therapy improvement was observed, remained intoxication syndrome, pain in the joints. Lost weight. Consultation by a specialist with a diagnosis of chronic brucellosis" was sent to RLB. From epidemiological history: working on the farm, participates in the slaughter of livestock, consume dairy products are homemade.

Objectively - a state of moderate severity, active. The temperature of 37.8°C. the Skin and visible mucous clean, damp to the touch. Allpinouts is increased cervical and axillary lymph nodes. Lung auscultation-vesicular respiration, CDD - 23/minute. Heart tones are rhythmic, muffled, no noise, CSS - 106/minute. BP - 90/60 mm Hg Abdomen soft, liver dense to the touch, is 3 cm from under the right costal arch. The size of the liver by karlovu: 15-12-9 see enlarged spleen is Palpated.

Laboratory findings:

On/and the blood: Hb - 116 g/l; er - 4,5×1012; CPU - 0.8; Leukocytes - 6,6×109; P - 2; S - 63; L - 31; M - 4; ESR - 22 mm/hour.

Positive samples Wright, Hedderson, TPHA with erythrocyte Brucella diagnosticum, intradermal Allergy test Byrne.

On the basis of clinical and laboratory data of a patient diagnosed with chronic brucellosis, locomotor form, subcompensation stage.

The traditional treatment: chloramphenicol, streptomycin, voltaren, tumeric, Likopid.

Dynamics of clinical symptoms during treatment: temperature normalized on the 15th day of treatment, the headache disappeared on day 13 of treatment, General weakness on the 20th day of treatment, sweating on the 19th day of treatment, the chills on the 8th day of treatment, the pain in the knee joints on the 17th day of treatment, myalgia on day 8 of treatment, size of lymph nodes is normalized on the 20th day of treatment, tachycardia disappeared on day 12 of treatment, the blood pressure has returned to normal on day 11 of treatment (120/80 mm Hg), liver decreased by 24 days of treatment, the spleen n the 20 day treatment is not even royalty.

The results of the PCT test. Before treatment: CFAC - 74%; CFA - 0,7; FMC - 11%; CAPM to 0.6. After treatment: CFAC - 64%; CFA - 1; FMC - 18%; CAFM - 1,1.

The results of the study thioldisulfide link AOC blood. Before treatment: SS-band - 4.9 mmol/l; SH-groups - 9.3 mmol/l; TDS - 1,8. After treatment: SS-band - 4.7 mmol/l; SH-group and 10.8 mmol/l; TDS - 2,3.

The patient was discharged on the 24th day of treatment with improvement recommendation further observations and surveys in KEYES residence.

Example 2. Patient, 54 years old (case history No. 1398) enrolled in the national center for infectious diseases Makhachkala 13.04.06, At admission the patient complained of temperature up to 38°C, pain, swelling and limitation of motion in the knee and ankle joints, myalgia, headache, weakness, fatigue, sweating, chills.

From the anamnesis: sick himself believes in 2004, the disease began with fever, joint pain, sweating, weakness, and tiredness. The patient was repeatedly treated in inpatient and outpatient, therapy was noted temporary improvement.

From epidamnus: patient contains large and small cattle in the farmlands, works as a butcher in the local market.

Objectively: the state of moderate severity. Temperature of 38°C. the Skin clean, moist to the touch. Palpable increase the nye neck, inguinal and axillary lymph nodes. In the lungs are heard and vesicular respiration, the number of respiratory movements 20 per minute. Heart sounds rhythmic, muted. Heart rate is 112 per minute. Blood pressure 100/65 mm Hg Abdomen is soft, painful in the right hypochondrium, liver stands out from the edge of the right costal arch on 3 see the size of the liver by karlovu 15×12×9 see enlarged spleen is Palpated.

Complete blood count: hemoglobin 115 g/l, erythrocytes-3,5×1012/l, color index is 0.8, erythrocyte sedimentation rate of 28 mm/h, WBC of 7.2×109/l, eosinophils 3%, stab 4%, segmented neutrophils 65%, lymphocytes 22%, monocytes 6%.

Positive reactions Wright, Hedderson, RIGA with erythrocyte Brucella diagnosticum, positive intradermal Allergy test Byrne (4×6 cm).

On the basis of clinical and laboratory data of a patient diagnosed with chronic brucellosis, locomotor form, subcompensation stage.

Treatment doxycycline 0.1 g 2 times a day inside 20 days, streptomycin, 0.5 g 2 times a/m 10 days, diclofenac 50 mg 2 times a day inside the 7 days, diazolinum 50 mg 2 times a day inside 15 days, tamerica/m 0.1 g 2 times a day for 10 days, followed by 0.1 g of 1 times in day of 10 days, Likopid 10 mg 2 times a day inside 20 days.

Dynamics of clinical symptoms on f is not treatment: temperature normalized on day 12 of treatment, headache disappeared on day 10, General weakness - on the 16th day, sweating - on the 11th day, chills, 9 day, pain in the joints - on the 17th day, myalgia - on day 5, tachycardia on day 6 19 day normalized size of the liver and spleen.

The results of the NBT-test:
CFAC, %CFAFMC, %CAFM
Before the treatment740,7110,6
After the treatment641181,1
CFAC - the number of functionally active cells; CFA - factor functional activity of monocytes; FMC - number faguoqitirute monocytes; CAFM - factor activity of phagocytosis in monocytes.
The results of the study thioldisulfide link AOC blood:
SH - groups, mmol/lSS - groups, mmol/lTDK(SH/SS)
Before the treatment9,3a 4.91,8
After the treatment10,8the 4.72,3
SS - disulfide group; SH - sulfhydryl group; TDK - thioldisulfide factor.

Electrocardiography: to ensure HR 101 min, PQ 0,17 with, QRS 0.1 s, QT 0.4 sec, the reduction of the voltage of the T wave in aVF and III leads; after treatment HR 71 min, PQ 0,17 with, QRS 0,09 c, QT 0,38 c.

Echocardiography: PL 3.6 cm, BWW 108 ml, CSR 50 ml, PP 58 ml, MOS - 2.8 l/min, SVR - 1612 dyns/cm5, TSKJ 0.9 cm, tmip - 0.9 cm, Dlasr 11 mm Hg; after treatment PL 3.5 cm, BWW 134 ml, CSR 52 ml, PP 82 ml, MOS - 4.2 l/min, SVR - 1211 dyns/cm5, TSKJ 0.9 cm, tmip - 0.9 cm, Dlasr 12 mm Hg

The patient was discharged on the 26th day of inpatient treatment in a satisfactory condition, it is noted increased to normal indicators of the functional status of the antioxidant system and mononuclear-phagocytic immunity.

Example 3. A female patient, 44 years, storeability No. 2233, he entered RCIB Makhachkala 30.03.05, with complaints of high fever, headache, General weakness, fatigue, sweating, vomiting; pain, swelling and limitation of motion in the joints (knee, ankle), myalgia. From an. morbi: the illness started 2 years ago with fever, pain in the joints. From epidemiological anamnesis: on the farm contains cattle.

Objectively - a state of moderate severity, active. Temperature - 38°C. the Skin and visible mucous clean, damp to the touch. Palpable enlarged cervical, inguinal and axillary lymph nodes. Lung auscultation-vesicular respiration, CDD - 24/minute. Heart tones are rhythmic, muffled, no noise, CSS - 108/minute. BP - 90/60 mm Hg Abdomen is soft, painful in the right hypochondrium, liver dense to the touch, acts 2 cm from the edge of the right costal arch. The size of the liver by karlovu: 14-12-9 see enlarged spleen is Palpated.

Laboratory findings:

On/and the blood: Hb - 130 g/l; er - 4,2×1012; CPU - 0,9; Leukocytes is 6.8×109; Uh - 1, P - 1; S - 67; L - 26; M - 5; ESR - 20 mm/hour.

Positive reactions Wright, Hedderson, TPHA with erythrocyte Brucella diagnosticum, intradermal Allergy test Byrne.

On the basis of clinical and laboratory data of a patient diagnosed with chronic Bruce the lez, locomotor form at the stage of subcompensation.

Treatment: chloramphenicol, streptomycin, voltaren, calcium gluconate, tumeric, Likopid.

Dynamics of clinical symptoms during treatment: temperature normalized on day 11 of treatment, the headache disappeared on day 10 of treatment, General weakness - on the 17th day of treatment, sweating on the 16th day of treatment, the chills on the 5th day of treatment; pain in the joints - on the 19th day of treatment, myalgia - on the 4th day of treatment, tachycardia disappeared on day 9 of treatment, on the 8th day of treatment normalized blood pressure (110/70 mm Hg), the size of the liver returned to normal on the 17th day of treatment, the spleen on the 15th day treatment is not even royalty.

The results of the PCT test. Before treatment: CFAC - 76%; CFA - 0,6; FMC - 12%; CAPM to 0.6. After treatment: CFAC - 55%; CFA - 1,4; FMC - 26%; CAPM in 1.5.

The results of the study thioldisulfide link AOC blood. Before treatment: SS-band - 4.8 mmol/l; SH-groups - 9.3 mmol/l; TDS is 1.9. After treatment: SS-group - 4.5 mmol/l; SH-group is 11.9 mmol/l; TDS - 2,6.

The patient was discharged with improvement of General condition 24 day treatment recommendation further observations in KEYES residence.

As can be seen from the examples presented, the patients who received integrated treatment using tamerica and licopid noted earlier disappearance of clinical symptoms and normalization of parameters of mononuclear-phage is citarny and antioxidant systems.

To study the influence of tamerica and licopid on the functional state thioldisulfide element of the antioxidant system and mononuclear-phagocytic immune system we conducted a survey of 162 patients with chronic brucellosis under sub - and decompensation.

Diagnosis of brucellosis was confirmed by the positive results of the reaction Wright and Hedderson, TPHA with erythrocyte Brucella diagnosticum, intradermal breakdown Byrne. Patients were randomized into 2 groups, of these, 76 patients received conventional therapy (group 1)and 86 patients - antioxidant tumeric and immunomodulator Likopid on the background of traditional therapy (group 2). As a control were studied 30 healthy persons Healthy persons and patients with brucellosis by age and sex were representative.

Patients of group 1 received conventional therapy antibiotics (doxycycline, streptomycin, ciprofloxacin) within 10-14 days of intermittent courses, non-steroidal anti-inflammatory drugs (diclofenac or piroxicam) and desensibilisation means (Dimedrol, suprastin or diazolinum). Patients of group 2 on the background of traditional therapy received antioxidant drug tumeric for 4 weeks and immunomodulator Likopid - within 3 weeks.

Table 1
Time (in days) the disappearance of clinical symptoms in the treatment of patients with chronic brucellosis different methods
SymptomsGroup 1 (n=86)Group 2 (n=76)
General weakness9,9±0,47,9±0,4*
Sweating16,7±0,414,6±0,3*
Headache8,3±0,46,0±0,3*
Fever7,6±0,35,6±0,3*
Arthralgia23,9±0,520,9±0,4*
Myalgia12,6±0,49,5±0,3*
The lymphadenopathy32,8±0,530,5±0,4
Hepatomegaly24,8±0,621,3±0,4*
Splenomegaly25,3±0,323,2±,3*
Note. * - difference significant at P<0.05 for student criterion compared with group 1. ABOUT acute brucellosis; HB - chronic brucellosis.

The state of AOC studied by quantitative determination of SH and SS groups in the hemolysate direct and inverse amperometric titration [Sokolov V.V. Thioldisulfide the ratio of blood as an indicator of the state of nonspecific resistance of the organism. - SPb., 1996. - 30 seconds]. Thioldisulfide ratio (TDS) was determined by calculating the ratio of sulfhydryl and disulfide groups of SH/SS.

We evaluated the clinical effectiveness of different methods of treatment of patients with chronic brucellosis. On the background of the treatment of patients of group 2 with the inclusion of tamerica and licopid is marked shortening of hospital treatment and the disappearance of clinical symptoms (arthralgia, headache, sweating, fever, General weakness) on average 2-4 days compared with group 1 (table 1).

This suggests that the AOC in patients with chronic brucellosis is experiencing excessive stress and is noted for her exhaustion, i.e. it does not cope with the increased level of free-radical oxidation and itself undergoes inactivation, which in the following is one of the main reasons for the excessive activity and lipid peroxidation.

As can be seen from table 2, the treatment of patients with chronic brucellosis in group 2 were more effective than in group 1. All parameters AOC in group 2 patients with chronic brucellosis after treatment became normal in group 1 only returned to near normal.

Table 2
The content of sulfhydryl groups (SH) and disulfide bonds (SS) in patients with chronic brucellosis after traditional treatment, as well as tamerica and Likopid on the traditional treatment (M±m)
OptionsHealthy individuals (n=30)Chronic brucellosis (n=162)
Group 1 (n=76)Group 2 (n=86)
SH, mmol/l11,0±0,0910,22±0,06*11,04±0,07
SS, mmol/l4,5±0,17of 5.89±0,04*4,5±0,03
SH/SS2,64±0,071,73±0,005*2,45±0,01*

When compared with normal values is the same as a serviceable parameters AOC in patients with chronic brucellosis after therapy in group 1 were far from the norm, and in group 2 - they almost came to the norm (see drawing).

Thus, in patients with brucellosis there is a decrease in reduced forms (SH) and increased oxidized forms (SS), respectively, decrease in TDK, which indicates the decrease in buffer capacity thioldisulfide link AOC and develops functional insufficiency of antioxidant protection. The use of antioxidant and immunomodulator in the treatment of patients with brucellosis showed higher clinical efficacy compared with traditional therapy. Investigating the effect of different methods of treatment of patients with brucellosis indicates an increase of sulfhydryl groups, reducing disulfide groups, and consequently, to increase TDK, i.e. normalization of the redox processes, the improvement of the functional status of the AOC on the background of the treatment with the inclusion of antioxidant and immunomodulatory drugs. This allows us to recommend a comprehensive antibiotic-antioxidant-together with immunomodulating therapy of patients with brucellosis.

As can be seen from table 3, in patients with chronic brucellosis on the background of traditional therapy show statistically significant compared with baseline values decreased CFAC (P=0,0003) and the increase in CFA (P=0,018), FMC (P=0.002) and CAPM (P=0.007).

The inclusion of tamerica and licopid in complex therapy Bo is lnyh chronic brucellosis contributes to a more pronounced decrease in CPAC (P=0.007) and increased CFA (P=0.002), FMC (P<0.001) and CAPM (P=0.0008).

Table 3
Dynamics of indicators of the mononuclear-phagocytic system in the blood of patients with chronic brucellosis in various methods of treatment (M±m)
OptionsGroup 1 (n=76)Group 2 (n=86)
Before the treatmentAfter the treatmentBefore the treatmentAfter the treatment
CFAC, %65,8±1,559±0,8*65±1,957,5±1,4*
CFA0,9±0,081,2±0,05*1,04±0,081,4±0,04*
FMC, %18±122,6±0,9*17,8±127,7±0,7*
CAFM1,05±0,11,4±0,06*1,19±0,091,5±0,04*
Note. CFAC - the number of functionally active cells; CFA - factor functional activity of monocytes; FMC - number faguoqitirute monocytes; CAFM - factor activity of phagocytosis in monocytes.
* - P<0,01 compared with values before treatment to student criterion.

The results of the research performance of mononuclear-phagocytic system in patients with chronic brucellosis indicate that when conventional therapy (group 1) improves the functional condition of monocytes and phagocytes, however, when therapy tamerica and licopid (group 2) normalization of all parameters of the mononuclear-phagocytic system.

The duration of inpatient treatment group 1 was on average 29±4 days, patients of group 2 - 24±3 days. After discharge from hospital, patients were followed for 3 years, during this period, 31% of patients of group 1 were hospitalized again with exacerbation of the disease, while patients of group 2 in 12% of cases. The results of complex treatment using tamerica and licopid patients with chronic brucellosis indicate not only the clinical laboratory, but also economic efficiency by reducing the time of inpatient treatment and the frequency of repeated Mr. the of talisay, patients almost 3 times compared to traditional therapy.

The obtained data demonstrate the feasibility of using this combination of drugs for the treatment of patients with chronic brucellosis.

Signs, distinctive features of the prototype:

1) is studied, in addition to clinical and laboratory parameters, the functional state of the antioxidant and immune systems in patients with chronic brucellosis;

2) is assigned to combined therapy with the inclusion of antioxidant and immunomodulatory drugs, taking into account the identified deviations of indicators of clinical and laboratory research;

3) comprehensive treatment of patients with chronic brucellosis using tamerica and licopid provides the best clinical, laboratory, and economic efficiency by reducing the time of inpatient treatment and the frequency of readmissions of patients compared with traditional therapy.

The positive effect

The positive effect is provided by using the proposed method in the treatment of patients with chronic brucellosis and prevents unfavorable course and outcome of the disease, improves the functional condition of the antioxidant and immune systems, reduces time inpatient treatment promotes long-term remission.

Method of treatment of chronic Brucella is om, including the introduction of antibacterial, antioxidant and immunomodulatory drugs, characterized in that the antioxidant drug use tumeric and as an immunomodulating drug - Likopid in therapeutic doses.



 

Same patents:

FIELD: medicine.

SUBSTANCE: therapy involves standard etiotropic treatment and electrophoresis in projection of affected pulmonary region. Electrophoresis starts from the first day of treatment, daily with using 50% aqueous solution of honey. Two-pole exposition takes 15 minutes. If both lungs affected, electrophoresis covers both lungs sequentially, 10 procedures for each. Unilateral pulmonary lesion requires 20 procedures.

EFFECT: higher clinical effectiveness for pulmonary tuberculosis patients and disease reduction ensured by improved rates of decay cavity closure, infiltrative changes resolution, abacillation.

1 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: pharmaceutical composition for making a parenteral preparation contains a pharmaceutical agent, a water-soluble polymer, a nonpolymeric additive and a solvent. The water-soluble polymer is chosen from the group: dextran, gelatin, 2-hydroxyethy starch, poly(N-vinylpyrrolidone), human blood serum albumin or their mixture. The nonpolymeric additive is chosen from the group: (C10-C18)acyl-sorbite, oligooxyethylene(C10-C18)acyl-sorbite, (C10-C18)alkyl oligooxyethylene glycol ester. The solvent represents mixed water and ethanol, or dimethyl sulphoxide, or N-methyl-2-pyrrolidone, or 2-pyrrolidone. The pharmaceutical agent, said water-soluble polymer, nonpolymeric additive and residual solvent are found in the preparation as a noncovalent complex.

EFFECT: improved bioavailability of the pharmaceutical agents and therapeutic dose decline.

2 cl, 1 dwg, 1 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: pharmaceutical composition for making a parenteral preparation contains a pharmaceutical agent, a water-soluble polymer, a nonpolymeric additive and a solvent. The water-soluble polymer is chosen from the group: dextran, gelatin, 2-hydroxyethy starch, poly(N-vinylpyrrolidone), human blood serum albumin or their mixture. The nonpolymeric additive is chosen from the group: (C10-C18)acyl-sorbite, oligooxyethylene(C10-C18)acyl-sorbite, (C10-C18)alkyl oligooxyethylene glycol ester. The solvent represents mixed water and ethanol, or dimethyl sulphoxide, or N-methyl-2-pyrrolidone, or 2-pyrrolidone. The pharmaceutical agent, said water-soluble polymer, nonpolymeric additive and residual solvent are found in the preparation as a noncovalent complex.

EFFECT: improved bioavailability of the pharmaceutical agents and therapeutic dose decline.

2 cl, 1 dwg, 1 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention is applied for treatment of purulent wounds and burns, pyoinflammatory dermatopathies, and for acceleration of healing and improvement of wound healing conditions. The composition possesses antibacterial and necrolytic action; it contains an active complex of bacteriolytic and proteolytic enzymes - Lisoamidase, and a base for soft formulation of the composition. The base contains a thermally stable perfluororganic compound emulsion with gas-transport properties and mixed hydrophilic substances specified as follows: proxanol-268, polyethylene oxides, propylene glycol, dimexide, hyaluronic acid or sodium hyaluronate, sorbite, glycerine, aerosil. Besides, the composition can contain at least one desired additive chosen from: anaesthetic (Chinoxycaine, Trimecaine, Pyromecaine, Lidocaine or mixed), a reparative process stimulator (methyluracil, acetamine, ethadene, calcium pantothenate, Solcoseryl or mixed) or mixed. The composition is made in the form of ointment or gel, rectal suppositories or capsules.

EFFECT: extended application, enhanced therapeutic activity and ease of use; lower consumption of the active substance; ensured anaesthetising effect; improved microcirculation in wound tissues, managed inflammatory processes, additional stimulation of reparative processes.

6 cl, 2 tbl, 19 ex

FIELD: medicine.

SUBSTANCE: medicinal agent for inhibiting Helicobacter pylori bacteria represents a coniferous chlorophyll carotene paste. A pharmaceutical composition for inhibition for inhibiting Helicobacter pylori bacteria contains the coniferous chlorophyll carotene paste in therapeutically effective amount and pharmaceutically acceptable carriers and/or solvents. The coniferous chlorophyll carotene paste is applied as an active component of the pharmaceutical composition for inhibition for inhibiting Helicobacter pylori bacteria. The coniferous chlorophyll carotene paste is applied as a Helicobacter pylori bacteria inhibitor.

EFFECT: said agent and pharmaceutical composition based on this agent provides effective inhibiting Helicobacter pylori bacteria.

5 cl, 4 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: substance of the invention consists in introduction of a complex of biologically active additives and plant preparation factors separately, sequentially between meals. Said biologically active additives include propolis in the form of 20% propolis butter, bear fat, seal fat and eicosavitol. The plant preparations are aspen bark tincture, arrowwood and cranberry water, vitamin herb tea combined with iodine-active and farina. Therapeutic course of the biologically active additives and plant preparations is 82-84 days.

EFFECT: lower acuteness of infectious process, optimisation of specific immune response on the complex of infectious agents ensured by higher antigen-binding capacity of antibodies.

3 cl, 8 tbl

FIELD: medicine.

SUBSTANCE: to treat the patients with open hand injuries, 30 minutes prior to primary surgical procedure, lincomycin is introduced in forearm of the injured limb intravenously retrograde, with applying tubing. Introduction procedure is performed in the first and second postoperative days.

EFFECT: higher efficiency of preventing pyoinflammatory postoperative complications in open hand injuries damages in the patients at risk thereof due to high concentration of lincomycin in immediate proximity of a lesion.

FIELD: medicine.

SUBSTANCE: invention refers to application of 8-cyano-quinolone antibiotics for systemic medication of bacterial stomatopathies, notably in veterinary science.

EFFECT: higher effectiveness of antibiotics.

5 cl, 1 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: said preparation contains the components as follows, %: Lincomycin hydrochloride 2.0-4.0; Dioxidine 0.5-1.0; soft Monoglyceride 3.0; distilled Monoglyceride 3.0; Vaseline oil to 100. The preparation is applied to treat all forms of mastitis in lactating period. Prior to introduction thereof, udder secretion is milked dry from an affected portion and utilised; a dug is disinfected. Before use, the contents of a syrette or a bottle is heated up to 37°C, agitated thoroughly to a uniform suspension, a sterile syringe is filled with 10 ml thereof from the bottle. The syringe or the syrette is tightly pressed to outer orifice of teat canal. The preparation is introduced therein by careful pressing the syringe piston. After introduction, gentle massage of the affected dug follows bottom-up. Considering the severity of inflammatory process, the preparation is introduced in a dose 10 ml once a day (preferentially, after afternoon milking) every 24 hours to ensure complete recovery of the affected dug portion. (2-4 times).

EFFECT: improved therapeutic effectiveness.

9 tbl, 5 ex

FIELD: medicine biologically active additives.

SUBSTANCE: According to the invention, the immunobiological bactericidal preparation contains species-specific virulent bacteriophages and induced-virulence bacteriophages of Appelman's lytic activity at least 10-4 with respect to test strains and bacteria isolates recovered from a human body in filtrate, concentrate filtrate or in a dry biomass of a phage lysate filtrate of nonlysogenic bacteria and pharmaceutically acceptable desired additives. The preparation can be presented as ointment, suppository, powder, tablet or capsule. Declared immunobiological bactericidal preparation is prepared by sequential multiple passages of phages of bacteriophage preparations through test strains and nonlysogenic bacteria isolates fresh-recovered from a human body with an inducing agent, eg mitomycin C, added to nutrient medium. According to the invention, the immunobiological bactericidal preparation provides stable virulence of bacteriophages and adaptation thereof to circular agents of bacterial infections.

EFFECT: higher clinical effectiveness.

13 cl, 9 tbl, 30 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular to gastroenterology and cardiology and concerns method of objectifying indications for choosing treatment of patients with ulcer disease (UD) in combination with artery hypertension (AH). For this purpose in accordance with WHO/ISAH classification of 1999, degree of AH and risk of development of cardio-vascular complications (RDCVC) is determined for patients. Patients with UD in combination with AH of I degree and RDCVC of 1-4 degree, as well as patients with UD with AH of II degree and RDCVC of 2 degree undergo traditional anti-ulcer and conventional hypertension therapy. Patients with UD and AH of II degree and RDCVC of 3-4 degree and patients with UD and AH of III degree and RDCVC of 4 degree are examined for presence of immune disorders, intestine disbacteriosis, depressive disorders, sympaticotonia, metabolic syndrome. If said disorders are found immunomodulators, antidepressants, vegetotropic medications are administered and metabolic syndrome therapy is performed, as hypotensive medications ACE inhibitors are introduced. Patients with UD with AH of III degree and RDCVC of 4 degree are administered combined therapy with ACE inhibitors and pulse slowing calcium antagonists, excluding preparations with make QT interval longer.

EFFECT: method ensures individualised treatment of said category of patients taking into account unfavourable development of ulcerous process depending on expression of systemic microcirculation disorders, determined by AH and RDCVC degree, which allows to influence different links of pathologic process fully and prevent development of complications.

8 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention concerns a pharmaceutical industry, in particular to an agent for improvement of functions of a pancreas. A medical product for improvement of pancreas functions, which contains certain bond. A medical product for improvement of pancreas functions, which contains an extract of a plant of Liliaceae family or its fraction, containing certain bond as an active ingredient. A foodstuff or a drink for improvement of functions of a pancreas which contains certain bond. A foodstuff or a drink for improvement of functions of a pancreas which contains an extract of a plant of family Liliaceae or its fraction containing certain bond as an active ingredient. Application of certain bond, or the extract containing specified bond for manufacture of a medical product for improvement of functions of a pancreas. Method of improvement of functions of a pancreas which includes introduction of certain bond, or the extract containing specified bond, to the subject which functions of a pancreas should be improved.

EFFECT: above described medical product, foodstuff or a drink effectively improve pancreas function.

17 cl, 4 dwg, 3 tbl, 7 ex

FIELD: medicine.

SUBSTANCE: invention claims application of naphthalene derivatives: ethylene blue, anthracene, acridine orange, acriflavine, toluidine blue, violamine R, green sulfonic acid, as cancer cell growth inhibitor for treatment of oncology diseases. Application involves administration of medicine up to three times per day by one-time dosage of 0.1 mg to 2 g in the form of solution or inhalation or water solution. Simultaneously medicine is administered rectally or intravenously in the form of 1-5% ointment or suppository. Tumour and metastasis regression is achieved under effect of indicated compounds for osteosarcoma with metastases in lungs, kidney cancer, ovary carcinoma, squamous cell carcinoma, prostate or rectum adenocarcinoma (with metastases to liver), lymphoma, hepatoma, glioblastoma etc. During therapy tumour and metastases disappeared, blood and urine analyses and patient's weight returned to normal. No recurrences have been registered in 4 years.

EFFECT: obtaining medicine inhibiting cancer cell growth for oncology disease treatment.

10 cl, 3 dwg, 17 ex, 6 tbl

FIELD: medicine.

SUBSTANCE: after primary virus remission, Ronkoleukine is introduced in dosage 500 mg with water 200 ml after supper within common interferon therapy, thus taking two courses 5-10 times every second day or 2 times a week. After the third introduction of Ronkoleukine, Likopide is additionally introduced in daily dosage 10 mg once a day within 10 days. Interval between courses is 2 months. If necessary courses are repeated.

EFFECT: prevented disease recurrence and eliminated immunodeficiency manifestation.

2 ex

FIELD: medicine; pharmacology.

SUBSTANCE: pharmaceutical composition contains Topyramat as active substance and additives, including starch, lactose, microcrystalline cellulose, cross-linked polyvinylpyrrolidone and dusting agent. Preparation is produced by wet granulation technique in the form of coated tablets with 25 mg, 50 mg, 100 mg or 200 mg of Topyramat content.

EFFECT: fast decomposition, high reactant release and high durability, storage stability.

10 cl, 1 tbl, 3 ex

FIELD: medicine; surgery.

SUBSTANCE: under intubation narcosis trocar laparocentesis is carried out in four points. Using endoscopic chamber of operation zone is visualised. Polytetrafluoroethylene film 0.5-1.0 mm thick sized by covered liver surface is prepared. Preliminary within 3 days film is kept in concentrated silver solution and Licopid dissolved in 0.9% sodium chloride solution. This film is envelope-like folded, seized with forceps and inserted to abdominal cavity through the most convenient trocar point. Using manipulator it is spread over all diaphragmatic liver surfaces. Film is lined in four points alongside liver parenchyma edges.

EFFECT: lower operative injury and intoxication; complex immunomodulating, antibacterial, antiviral, antitumor and antiinflammatory activity directly in pathology zone.

2 ex

FIELD: medicine; pharmacology.

SUBSTANCE: method of treatment or prevention of hyperlipidemia conditions and/or hypercholesterinemia implies application of composition containing cyanidin-3-O-glucoside and peonidine-3-O-glucoside. Composition contains therapeutically effective amount of black rice extract, including cyanidin-3-O-glucoside, peonidine-3-O-glucoside and one or more phytosterols and/or phytostanines. Composition contains therapeutically effective amount of black rice extract, including cyanidin-3-O-glucoside, peonidine-3-O-glucoside and one or more antioxidants. Method of treatment or prevention of hyperlipidemia conditions and/or hypercholesterinemia implies application of composition containing extract of hulled black rice external layer, thus the specified extract contains cyanidin-3-O-glucoside and peonidine-3-O-glucoside.

EFFECT: efficiency for treatment or prevention hyperlipidemia conditions and hypercholesterinemia.

29 cl, 19 dwg, 11 tbl, 11 ex

FIELD: medicine, pharmacology.

SUBSTANCE: invention relates to application of ethanol extract obtained from dried rhizome of Long-Bracted Green Orchid (Wangla, Coeloglossum viride (L) Hartm. Var. Bracteatum (Wild.) Richter), derivatives of siccine acid ethers of formula: where R1 and R4 are selected from -OCH3, -OH, -OGlu, and R2 and R3 are selected from H, -OH, -OGlu, and R5 is selected from branched and non-branched C1-6 alkyls, for dementia treatment, particularly, for treatment of Alzheimer-disease and vessel dementia. In addition, invention relates to pharmaceutical compositions including said extract or compounds.

EFFECT: high activity and low toxicity.

14 cl, 4 dwg, 8 tbl, 7 ex

FIELD: medicine; stomatology.

SUBSTANCE: tooth extraction is followed by 5-minutes processing of bone cavity with wave guide "Optodan" with the semiconductor laser diode, generating pulse light of wave length within 0.85 to 0.98 microns. Pulse power is 2-4 W, pulse duration is 40-100 nm, and pulse frequency is 1.5-2.0 kHz, magnetic field intensity is 35 mTl. Cavity is processed through miramystine solution; washed with 30% lincomycin hydrochloride solution and 1 % dioxidyn solution taken in ratio 3:1. Then bone wound is filled with bioresorbed osteoplastic material "AlgOss" with size of granules by 0.25, 0.5 and 1 mm depending on bone defect size by 2/3 of volumes. Wound is isolated mouth cavity with film "Diplen-denta" with lincomycin.

EFFECT: method provides bone grafting with minimum postoperative complications owing to creation of depot medicinal agents in wound and stimulations of regenerative processes.

4 ex

FIELD: medicine, allergology.

SUBSTANCE: invention relates to treatment of allergic diseases, in particle, bronchial asthma. Invention proposes using black rice extract or pelargonidine, or cyanidine-glycoside for development of a therapeutic agent. These agents are used in the developed therapeutically effective doses. Invention provides effective treatment based on inhibition of accumulation of eosinophyles in cells of damaged tissues and organs.

EFFECT: enhanced and valuable medicinal properties of composition.

13 cl, 1 tbl, 4 dwg, 6 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine, namely to infectious diseases, and can be used in therapy of the patients suffering from acute brucellosis. This therapy is ensured by a conventional therapeutic complex including introduction of antibacterial agents. Additionally, pharmacotherapy includes Tamerite.

EFFECT: method provides clinical recovery, reduced treatment time ensured by optimum adjustment of specific antioxidant and immunomodulator for such disease as acute brucellosis, as well as by strengthening of antiinflammatory effect.

2 ex, 5 tbl, 3 dwg

Up!